EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia

Juliana Holasova, Ludmila Demitrovicova, Andrej Vranovsky, Juraj Chudej, Emilia Flochova, Lubica Valekova, Natalia Stecova, Katarina Uzikova, Monika Hlebaskova, Hilda Sajgalikova, Zuzana Sninska, Firas Farkas und 2 weitere

Lymphatics · 09.07.2026 · 4 (3) · 35

DOI: 10.3390/lymphatics4030035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lymphatics, online erschienen am 09.07.2026. Verfasst von Juliana Holasova und 13 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted therapy, resulting in improved outcomes and patient survival. The aim of this study was to evaluate the efficacy and safety of venetoclax-based regimens in patients with relapsed/refractory CLL, as well as their effectiveness in patients previously treated with ibrutinib. We retrospectively analyzed 98 patients with CLL who received venetoclax in the second or later lines of therapy in Slovakia between 2018 and 2024. The median age was 68 years, and treatment was administered either as monotherapy or in combination with rituximab. Response to treatment was assessed according to the iwCLL 2018 criteria and clinical practice. Patients who achieved complete hematologic and clinical remission but did not undergo confirmatory bone marrow examination were classified as having unconfirmed complete remission (uCR). An overall response was achieved in the majority of patients (in 99%), with 2% achieving complete remission, 65% incomplete complete remission and 32% partial remission. At a median follow-up of 34 months, median overall survival was not reached (mean 52.5 months), and median progression-free survival was 45 months. Survival outcomes were evaluated using Kaplan–Meier analysis. Patients previously treated with ibrutinib had significantly worse outcomes (p = 0.022). Adverse events were predominantly hematological (64%), with 19% being grade 3–4. In line with the conclusions of clinical trials and retrospective analysis from real-life practice, we can say that venetoclax-based treatment regimens are highly effective in patients with CLL in higher lines of treatment, with acceptable and well-manageable toxicity.

Zitieren

APA

Holasova, J., Demitrovicova, L., Vranovsky, A., Chudej, J., Flochova, E., Valekova, L., Stecova, N., Uzikova, K., Hlebaskova, M., Sajgalikova, H., Sninska, Z., Farkas, F., Wild, A., & Hrubisko, M. (2026). Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia. Lymphatics, 4(3), 35. https://doi.org/10.3390/lymphatics4030035

Vancouver

Holasova J, Demitrovicova L, Vranovsky A, Chudej J, Flochova E, Valekova L, et al. Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia. Lymphatics. 2026;4(3):35. doi:10.3390/lymphatics4030035

BibTeX
@article{Holasova2026,
  author = {Holasova, Juliana and Demitrovicova, Ludmila and Vranovsky, Andrej and Chudej, Juraj and Flochova, Emilia and Valekova, Lubica and Stecova, Natalia and Uzikova, Katarina and Hlebaskova, Monika and Sajgalikova, Hilda and Sninska, Zuzana and Farkas, Firas and Wild, Alexander and Hrubisko, Mikulas},
  title = {Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia},
  journal = {Lymphatics},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {35},
  doi = {10.3390/lymphatics4030035}
}
Kostenlos starten →